ResMed’s Growth Outlook Trails Its Recent Revenue Pace
StockStory points to ResMed’s cash generation as a strength, while analysts expect slower revenue growth over the next 12 months.
Key takeaways
- ResMed’s constant-currency revenue grew by an average of 8.9% annually over two years.
- Analysts expect revenue to rise 2.7% over the next 12 months, according to StockStory.
ResMed shares were quoted at $218.94 in StockStory’s analysis, down 2.7% over six months, while the S&P 500 gained 15.9%. In Monday afternoon trading, the stock was $223.35, up 2.04% since the previous close.
StockStory highlighted ResMed’s average 8.9% annual growth in constant-currency revenue over the past two years. It also noted the company’s trailing 12-month free cash flow margin was 29.2%.
Wall Street analysts expect revenue to grow 2.7% over the next 12 months, below the 12.1% annualized rate of the past five years, according to StockStory. The article cited a forward price-to-earnings ratio of 18.2 at its $218.94 share price.
This article was produced with the help of AI technology. Source: Yahoo Finance
